This is a succinct and current review of pertinent literature to guide developing serum therapy as an emergent treatment to save human lives at times of natural or genetically engineered viral/bacterial pandemics. The origin of 2019-nCoV and implications of COVID-19 are discussed using direct quotes of published scientific literature to avoid misinterpretation on this very important event that has caused great loss of human lives and international social economy. It is the goal of this review to warn against and to correct international misunderstanding created by deliberate falsification of scientific documentations and events. This misunderstanding may lead to further destruction of life, economy, and political relations. People should not be blind-sighted when making life decisions.
References
[1]
Sherwood Romer, A. (1945) Vertebrate Paleontology. University of Chicago Press, Chicago, IL, 687 p.
[2]
Hand, S.J., et al. (2009) Bats that Walk: A New Evolutionary Hypothesis for the Terrestrial Behaviour of New Zealand’s Endemic Mystacinids. BMC Evolutionary Biology, 9, 169. https://doi.org/10.1186/1471-2148-9-169
[3]
Boulikas, T. (1998) Status of Gene Therapy in 1997: Molecular Mechanisms, Disease Targets, and Clinical Applications. Gene Therapy & Molecular Biology, 1, 1-172.
[4]
Coutarda, B., Valleb, C., de Lamballeriea, X., Canardb, B., Seidahc, N.G. and Decroly, E. (2020) The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furinlike Cleavage Site Absent in CoV of the Same Clade. Antiviral Research, 176, Article ID: 104742. https://doi.org/10.1016/j.antiviral.2020.104742
[5]
Kessler, D.A., Siegel, J.P., Noguchi, P.D., Zoon, K.C., Feiden, K.L. and Woodcock, J. (1993) Regulation of Somatic Cell-Therapy and Gene Therapy by the Food and Drug Administration. The New England Journal of Medicine, 329, 1169-1173. https://doi.org/10.1056/NEJM199310143291607
[6]
Law, P.K., Bertorini, T., Goodwin, T.G., Chen, M., Fang, Q.W., Li, H.J., et al. (1990) Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy. The Lancet, 336, 114-115. https://doi.org/10.1016/0140-6736(90)91628-N
[7]
Wikipedia (2013) William French Anderson. https://en.wikipedia.org/wiki/William_French_Anderson
[8]
Kolata, G. (1990) Cell Transplant Found Effective in Muscle Disease: Muscular Dystrophy Patient Showed Strength Increase in First Test. New York Times.
[9]
Law, P.K. (2016) Disease Prevention and Alleviation by Human Myoblast Transplantation. Open Journal of Regenerative Medicine, 5, 25-43. https://doi.org/10.4236/ojrm.2016.52003
[10]
Anderson, W.F. (1990) Editorial. The Beginning. Human Gene Therapy, 1, 371-372. https://doi.org/10.1089/hum.1990.1.4-371
[11]
Anderson, W.F. (1992) Human Gene Therapy. Science, 256, 808-813. https://doi.org/10.1126/science.1589762
Crystal, R.G. (1997) Transfer of Genes to Humans: Early Lesions and Obstacles to Success. Science, 270, 404-410. https://doi.org/10.1126/science.270.5235.404
[14]
Verma, I. and Somia, N. (1997) Gene Therapy—Promises, Problems and Prospects. Nature, 389, 239-242. https://doi.org/10.1038/38410
[15]
Thomas, C.E., Ehrhardt, A. and Kay, M.A. (2003) Progress and Problems with the Use of Viral Vectors for Gene Therapy. Nature Reviews Genetics, 4, 346-358. https://doi.org/10.1038/nrg1066
[16]
Culver, K.W. (1996) The First Human Gene Therapy Experiment. In: Culver, K.W., Ed., Gene Therapy: A Primer for Physicians, Mary Ann Liebert, Inc., New York, 47-53.
[17]
Brenner, M.K. (1995) Human Somatic Gene Therapy: Progress and Problems. Journal of Internal Medicine, 237, 229-239. https://doi.org/10.1111/j.1365-2796.1995.tb01171.x
[18]
DeLisi, C. (1988) The Human Genome Project. American Scientist, 76, 488-493.
[19]
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., et al. (2001) The Sequence of the Human Genome. Science, 291, 1304-1351. https://doi.org/10.1126/science.1058040
[20]
Venter, D. (2003) A Part of the Human Genome Sequence. Science, 299, 1183-1184. https://doi.org/10.1126/science.299.5610.1183
[21]
White House Press Release. Retrieved on 22 July 2006.
[22]
DeLisi, C. (2008) Meetings that Changed the World: Santa Fe 1986: Human Genome Baby-Steps. Nature, 455, 876-877. https://doi.org/10.1038/455876a
[23]
Collins, F. (2006) The Language of God: A Scientist Presents Evidence for Belief. Free Press, New York.
[24]
Beardsley, T. (1990) Profile: Gene Doctor. W. French Anderson Pioneers Gene Therapy. Scientific American, 263, 33. https://doi.org/10.1038/scientificamerican0890-33
[25]
Culver, K.W., Osborne, W.R., Miller, A.D., Fleisher, T.A., Berger, M., Anderson, W.F., et al. (1991) Correction of ADA Deficiency in Human T Lymphocytes Using Retroviral-Mediated Gene Transfer. Transplantation Proceedings, 23, 170-171.
[26]
Karlsson, S. (1991) Treatment of Genetic Defects in Hematopoietic Cell Function by Gene Transfer. Blood, 78, 2481-2492. https://doi.org/10.1182/blood.V78.10.2481.2481
[27]
Gonzaga-Jauregui, C., Lupski, J.R. and Gibbs, R.A. (2012) Human Genome Sequencing in Health and Disease. Annual Review of Medicine, 63, 35-61. https://doi.org/10.1146/annurev-med-051010-162644
[28]
Snyder, M., Du, J. and Gerstein, M. (2012) Personal Genome Sequencing: Current Approaches and Challenges. Genes & Development, 24, 423-431. https://doi.org/10.1101/gad.1864110
[29]
Collins, F. (2020) Genomic Study Points to Natural Origin of COVID-19. NIH Director’s Blog.
[30]
Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C. and Garry, R.F. (2020) The Proximal Origin of SARS-CoV-2. Nature Medicine, 17. https://doi.org/10.1038/s41591-020-0820-9
Ren, W., Qu, X., Li, W., Han, Z., Yu, M., Zhou, P., Zhang, S.Y., Wang, L.F., Deng, H. and Shi, Z (2008) Difference in Receptor Usage between Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-Like Coronavirus of Bat Origin. Journal of Virology, 82, 1899-1907. https://doi.org/10.1128/JVI.01085-07
[33]
Kuo, L., Godeke, G.J., Raamsman, M.J., Masters, P.S. and Rottier, P.J. (2000) Retargeting of Coronavirus by Substitution of the Spike Glycoprotein Ectodomain: Crossing the Host Cell Species Barrier. Journal of Virology, 74, 1393-1406. https://doi.org/10.1128/JVI.74.3.1393-1406.2000
[34]
Casais, R., Dove, B. Cavanagh, D. and Britton, P. (2003) Recombinant Avian Infectious Bronchitis Virus Expressing a Heterologous Spike Gene Demonstrates that the Spike Protein Is a Determinant of Cell Tropism. Journal of Virology, 77, 9084-9089. https://doi.org/10.1128/JVI.77.16.9084-9089.2003
[35]
Haijema, B.J., Volders, H. and Rottier, P.J. (2003) Switching Species Tropism: An Effective Way to Manipulate the Feline Coronavirus Genome. Journal of Virology, 77, 4528-4538. https://doi.org/10.1128/JVI.77.8.4528-4538.2003
[36]
de Haan, C.A., Kuo, L., Masters, P.S., Vennema, H. and Rottier, P.J. (1998) Coronavirus Particle Assembly: Primary Structure Requirements of the Membrane Protein. Journal of Virology, 72, 6838-6850. https://doi.org/10.1128/JVI.72.8.6838-6850.1998
[37]
Hou, Y., Peng, C., Yu, M., Li, Y., Han, Z., Li, F., Wang, L.-F. and Shi, Z. (2020) Angiotensin-Converting Enzyme 2 (ACE2) Proteins of Different Bat Species Confer Variable Susceptibility to SARS-CoV Entry. Archives of Virology, 155, 1563-1569. https://doi.org/10.1007/s00705-010-0729-6
[38]
Yu, M., Stevens, V., Berry, J.D., Crameri, G., McEachern, J., Tu, C., Shi, Z., Liang, G., Weingart, H., Cardosa, J., Eaton, B.T., Wang, L.F. (2008) Determination and Application of Immunodominant Regions of SARS Coronavirus Spike and Nucleocapsid Proteins Recognized by Sera from Different Animal Species. Journal of Immunological Methods, 331, 1-12. https://doi.org/10.1016/j.jim.2007.11.009
[39]
Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M., Xiang, H., Xia, X., Liu, S., Ren, T., Yu, Y., Eaton, B.T., Xuan, H. and Wang, L.F. (2004) Antibodies to SARS Coronavirus in Civets. Emerging Infectious Diseases Journal, 10, 2244-2248. https://doi.org/10.3201/eid1012.040520
[40]
Yount, B., et al. (2003) Reverse Genetics with a Full-Length Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus. Proceedings of the National Academy of Sciences of the United States of America, 100, 12995-13000. https://doi.org/10.1073/pnas.1735582100
[41]
Menachery, V.D., Yount Jr., B.L., Debbink, K., Agnihothram, S., Gralinski, L.E., Plante, J.A., Graham, R.L., Scobey, T., Ge, X.-Y., Donaldson, E.F., Randell, S.H., Lanzavecchia, A., Marasco, W.A., Shi, Z.-L. and Baric, R.S. (2015) A SARS-Like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence. Nature Medicine, 21, 1508-1513. https://doi.org/10.1038/nm.3985
[42]
Kaiser, J. (2014) Moratorium on Risky Virology Studies Leaves Work at 14 Institutions in Limbo. ScienceInsider. http://news.sciencemag.org/biology/2014/11/moratoriumrisky-virology-studies-leaves-work-14-institutions-limbo
[43]
Sheahan, T.P., Sims, A.C., Zho, S., Graham, R.L., Pruijssers, A.J., Agostini, M.L., et al. (2020) An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abb5883
[44]
Law, P.K. (2020) Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics. Open Journal of Regenerative Medicine, 9, 1-7. https://www.scirp.org/journal/ojrm https://doi.org/10.4236/ojrm.2020.91001
[45]
Law, P.K. (2020) System Engineering of Emergent Serum Therapy to Combat COVID-19 and Other Pathogenic Pandemics Open Journal of Regenerative Medicine, 9, 8-14. https://doi.org/10.4236/ojrm.2020.91002
[46]
Millet, J.K. and Whittaker, G.R. (2014) Host Cell Entry of Middle East Respiratory Syndrome Coronavirus after Two-Step, Furin-Mediated Activation of the Spike Protein. Proceedings of the National Academy of Sciences of the United States of America, 111, 15214-15219. https://doi.org/10.1073/pnas.1407087111
Law, P.K. (2017) Crime against Humanity. Open Journal of Regenerative Medicine, 6, 35-45. https://doi.org/10.4236/ojrm.2017.64004
[49]
Stennes, M.L. (1997) The Criminalization of Innovation: FDA Misdirection in the Najarian and Burzynski Cases (1997 Third Year Paper). Harvard Law School. http://nrs.harvard.edu/urn-3:HUL.InstRepos:9453691
[50]
Seife, C. (2016) FDA Documents Reveal Depths of Internal Rancor over Drug’s Approval Process. Undark. https://undark.org/article/fda-eteplirsen-janet-woodcock/
[51]
Law, P.K., et al (2019) Myoblasts Provide Safe and Effective Treatments for Hereditary Muscular Dystrophies, Cardiomyopathies, Type 2 Diabetes, Solid Tumors and Aging. In: Haider, K.H. and Aziz, S., Eds., Stem Cells—From Hype to Real Hope, Walter de Gruyter GmbH, Berlin, 71-97. https://doi.org/10.1515/9783110587043-004
[52]
Schoofs, T., Klein, F., Braunschweig, M., et al. (2016) HIV-1 Therapy with Monoclonal Antibody 3BNC117 Elicits Host Immune Responses against HIV-1. Science, 352, 997-1001. https://doi.org/10.1126/science.aaf0972
[53]
Lu, C.L., Murakowski, D.K., Bournazos, S., et al. (2016) Enhanced Clearance of HIV-1-Infected Cells by Broadly Neutralizing Antibodies against HIV-1 in Vivo. Science, 352, 1001-1004. https://doi.org/10.1126/science.aaf1279
[54]
ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al. (2006) Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 3, e237. https://doi.org/10.1371/journal.pmed.0030237
[55]
ter Meulen, J., Bakker, A.B., van den Brink, E.N., et al. (2004) Human Monoclonal Antibody as Prophylaxis for SARS Coronavirus Infection in Ferrets. The Lancet, 363, 2139-2141. https://doi.org/10.1016/S0140-6736(04)16506-9
[56]
Chu, C., Cheng, V., Hung, I., et al. (2004) Role of Lopinavir/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings. Thorax, 59, 252-256. https://doi.org/10.1136/thorax.2003.012658
[57]
Chan, K.S., Lai, S.T., Chu, C.M. et al. (2003) Treatment of Severe Acute Respiratory Syndrome with Lopinavir/Ritonavir: A Multicentre Retrospective Matched Cohort Study. Hong Kong Medical Journal, 9, 399-406.
[58]
Clark, D.R., Jonathan, E.M., et al. (2020) Clinical Evidence Does Not Support Corticosteroid Treatment for 2019-nCoV Lung Injury. The Lancet.
[59]
WHO (2020) Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
[60]
Lee, N., Chan, A., Hui, K.C., et al. (2004) Effects of Early Corticosteroid Treatment on Plasma SARS-Associated Coronavirus RNA Concentrations in Adult Patients. Journal of Clinical Virology, 31, 304-309. https://doi.org/10.1016/j.jcv.2004.07.006
[61]
Vincent, M.J., Bergeron, E., Benjannet, S., et al. (2005) Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infection and Spread. Virology Journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69
[62]
Bin, J., Qi, Z., Ge, X., Wang, R., Yu, J., Shan, S., et al. (2020) Potent Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. BioRxiv Preprint.
[63]
Holshue, M.L., DeBolt, C., Lindquist, S., et al. (2020) First Case of 2019 Novel Coronavirus in the United States. The New England Journal of Medicine, 382, 929-936. https://doi.org/10.1056/NEJMoa2001191
[64]
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., et al. (2015) The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-Analysis. The Journal of Infectious Diseases, 211, 80-90. https://doi.org/10.1093/infdis/jiu396
[65]
Chen, L., Xiong, J., Bao, L. and Shi, Y. (2020) Convalescent Plasma as a Potential Therapy for COVID-19. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30141-9
[66]
Zhou, J., Chu, H., Li, C., et al. (2014) Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis. The Journal of Infectious Diseases, 209, 1331-1342. https://doi.org/10.1093/infdis/jit504
[67]
Lai, S.T. (2005) Treatment of Severe Acute Respiratory Syndrome. European Journal of Clinical Microbiology & Infectious Diseases, 24, 583-591. https://doi.org/10.1007/s10096-005-0004-z
[68]
Soo, Y.O., Cheng, Y., Wong, R., et al. (2004) Retrospective Comparison of Convalescent Plasma with Continuing High-Dose Methylprednisolone Treatment in SARS Patients. Clinical Microbiology and Infection, 10, 676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x
[69]
Cheng, Y., Wong, R., Soo, Y.O., et al. (2005) Use of Convalescent Plasma Therapy in SARS Patients in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases, 24, 44-46. https://doi.org/10.1007/s10096-004-1271-9
[70]
Chippaux, J.-P., Boyer, L.V. and Alagón, A. (2015) Post-Exposure Treatment of Ebola Virus Using Passive Immunotherapy: Proposal for a New Strategy. Journal of Ven-omous Animals and Toxins including Tropical Diseases, 21, 3. https://doi.org/10.1186/s40409-015-0003-1
[71]
WHO (2020) Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks. http://apps.who.int/iris/rest/bitstreams/604045/retrieve
[72]
Arabi, Y., Balkhy, H. and Hajeer, A.H. (2015) Feasibility, Safety, Clinical, and Laboratory Effects of Convalescent Plasma Therapy for Patients with Middle East Respiratory Syndrome Coronavirus Infection: A Study Protocol. Springerplus, 4, 709. https://doi.org/10.1186/s40064-015-1490-9
[73]
WHO (2012) Middle East Respiratory Syndrome Coronavirus (MERS-CoV): MERS-CoV in Republic Korea at a Glance. http://www.wpro.who.int/outbreaks_emergencies/wpro_coronavirus/en
[74]
Hung, I.F., To, K.K., Lee, C.K., et al. (2011) Convalescent Plasma Treatment Reduced Mortality in Patients with Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases, 52, 447-456. https://doi.org/10.1093/cid/ciq106
[75]
Hung, I.F.N., To, K.K.W., Lee, C.K., et al. (2013) Hyperimmune IV Immunoglobulin Treatment: A Multicenter Double-Blind Randomized Controlled Trial for Patients with Severe 2009 Influenza A(H1N1) Infection. Chest, 144, 464-473. https://doi.org/10.1378/chest.12-2907
[76]
Mo, Y. and Fisher, D. (2016) A Review of Treatment Modalities for Middle East Respiratory Syndrome. Journal of Antimicrobial Chemotherapy, 71, 3340-3350. https://doi.org/10.1093/jac/dkw338
[77]
Marano, G. Vaglio, S., Pupella, S., et al. (2016) Convalescent Plasma: New Evidence for an Old Therapeutic Tool? Blood Transfusion, 14, 152-157.
[78]
Yang, X.M. and Hou, J.F. (2020) The Current Status of Convalescent Plasma’s Application in Acute Viral Infectious Diseases and Its Prospects in the Treatment of New Coronavirus Pneumonia. Chinese Journal of Biologicals, 1-5.
[79]
Cunningham, A.C., Goh, H.P. and Koh, D. (2020) Treatment of COVID-19: Old Tricks for New Challenges. Critical Care, 24, 91. https://doi.org/10.1186/s13054-020-2818-6
[80]
Amoss, H.L. and Chesney, A.M. (1917) A Report on the Serum Treatment of Twenty-Six Cases of Epidemic Poliomyelitis. Journal of Experimental Medicine, 25, 581-608. https://doi.org/10.1084/jem.25.4.581
[81]
Luke, T.C., Kilbane, E.M., Jackson, J.L. and Hoffman, S.L. (2006) Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 treatment? Annals of Internal Medicine, 145, 599-609. https://doi.org/10.7326/0003-4819-145-8-200610170-00139
[82]
Mcguire, L.W. and Redden, W.R. (1918) The Use of Convalescent Human Serum in Influenza Pneumonia: A Preliminary Report. American Journal of Public Health, 8, 741-744. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1362336 https://doi.org/10.1001/jama.1918.26020420013013e
[83]
WHO (2013) WHO-International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) MERS-CoV Outbreak Readiness Workshop. http://www.who.int/csr/disease/coronavirus_infections/MERS_outbreak_readiness_workshop.pdf
